Academic tech transfer keeps on spinning out startups, but the pool of capital to sustain such ventures is dwindling.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
Change history
10 May 2013
In the version of this article initially published, in Table 1, the percentage of money placed into profitable biotechs in 2012 was incorrectly listed as 0.49. The correct percentage is 0.44. Also, in Table 3, the investor group Edmond de Rothschild Investment Partners was incorrectly listed as Rothschild. In Table 5, the “Other” category for investment in therapeutic modalities in 2011 was incorrectly listed as 812; the correct amount is 841. In Table 7, the total number of life sciences spinouts over the 2008–2012 period was listed as 47,000. The correct number is 471. The callout for Figure 3 on p. 401, second column, was incorrectly labeled as Figure 2. Finally, the credit “ThinkStock” for the image on p. 396 was omitted. The errors have been corrected in the HTML and PDF versions of the article.
27 June 2013
In the version of this article initially published, in Table 3, Novo A/S was incorrectly identified as a venture arm of a pharma company. In fact, this entry should have read Novo Ventures, which is not a pharma venture arm, but a venture firm operated by Novo A/S. The error has been corrected in the PDF and HTML versions of this article.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Huggett, B. Biotech's wellspring: the health of private biotech in 2012. Nat Biotechnol 31, 396–403 (2013). https://doi.org/10.1038/nbt.2577
Published:
Issue date:
DOI: https://doi.org/10.1038/nbt.2577
This article is cited by
-
Erratum: Biotech's wellspring: the health of private biotech in 2012
Nature Biotechnology (2013)
